Cerevance Media Center

Current News

September 19, 2023

Cerevance Doses First Subject in Phase 1 Clinical Study of CVN293, a Selective Inhibitor of KCNK13 Designed to Selectively Modulate Neuroinflammation, for the Treatment of ALS and Alzheimer’s Disease

Cerevance today announced that the first subject has been dosed in the Phase 1 clinical study evaluating the safety, tolerability, and pharmacokinetics of CVN293.

READ FULL

August 28, 2023

Fierce Biotech Names Cerevance a “Fierce 15” Biotech Company of 2023

Cerevance has been named by Fierce Biotech as one of the most promising early-stage biotechnology companies in the industry in 2023, showcased on this year’s Fierce 15 list.

READ FULL

July 10, 2023

Cerevance to Present at the Alzheimers Association International Conference

Cerevance today announced plans to present a poster presentation at the upcoming Alzheimer’s Association International Conference (AAIC), taking place in Amsterdam, Netherlands, July 16 – 20, 2023.

READ FULL

June 28, 2023

Cerevance to Present at the XVI European Meeting on Glial Cells in Health and Disease

Cerevance today announced plans to present a poster presentation at the upcoming XVI European Meeting on Glial Cells in Health and Disease, taking place in Berlin, Germany, July 8 – July 11, 2023.

READ FULL

News Archive

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
No items found.

August 31, 2023

22nd Society of Chemical Industry / Royal Society of Chemistry Medicinal Chemistry Symposium

Date:
Thursday, August 31, 2023
Time:
8:30am
Location:
Cambridge, United Kingdom
Media:
Presentation
Read full

July 10, 2023

Alzheimers Association International Conference

Date:
Sunday, July 16, 2023
Time:
8:45am – 4:15pm
Location:
Amsterdam, Netherlands
Media:
Presentation
Read full

June 28, 2023

XVI European Meeting on Glial Cells in Health and Disease

Date:
Monday, July 10, 2023
Time:
1:00pm – 4:00pm
Location:
Berlin, Germany
Media:
Poster
Read full

Events Archive

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
No items found.

February 15, 2023

Characterisation of C101248: A novel selective THIK-1 channel inhibitor for the modulation of microglial NLRP3-inflammasome

Ossola, B., Rifat, A., Rowland, A., Hunter, H., Samuel Drinkall, S., Bender, C., Hamlischer, M., Teall, M., Burley, R., Barke1, D., Cadwalladr, D., Dickson, L., Lawrence, J., Harvey, J., Lizio, M., Xu, X., Kavanagh, E., Cheung, T., Sheardown, S., Lawrence, C.B., Harte, M., Brough, D., Madry, C., Matthews, K., Doyle, K., Page, K., Powell, J., Brice, N.L., Bürli, R.W., Carlton, M.B., Dawson L.A. (2023) Characterisation of C101248: a novel selective THIK-1 channel inhibitor for the modulation of m

view

November 21, 2022

Pharmacological Targeting of Glutamatergic Neurons within the Brainstem for Weight Reduction

Schneeberger, M., Brice, N.L., Pellegrino, K., Parolar,L., Shaked,J.T., Page,K., Marchildon, F., Barrows, D., Carroll, T.S., Tolpiko, T., Mulligan, V., Barker, D., Glen, A., Newman, R., Ortuño, M.J., Renier, N., Nectow, A.R., Cohen, P., Carlton, M., Heintz, N., Friedman, J.M. (2023) Development of an Orexin 1 Receptor Antagonist for Weight Reduction. Nat Metab. 4: 1495-1513.

view

June 1, 2022

Scalable Synthesis of CVN424, an Inverse Agonist of the GPR6 Receptor

Mu, CW, Li, XL, Yang, Y, Zhou, Y, Wan, CH, Doyle, KJ, Ye, ND, Mistry, A, Bürli, RW (2023) Scalable Synthesis of CVN424, an Inverse Agonist of the GPR6 Receptor. Org. Proc. Res. Dev. DOI: 10.1021/acs.oprd.2c00181

view

March 15, 2022

The Two Pore Potassium Channel THIK-1 Regulates NLRP3 Inflammasome Activation

Drinkall, S., Lawrence, C.B., Ossola, B., Russell, S., Bender, C., Brice, N.L., Dawson, L.A., Harte, M., Brough D. (2022) The Two pore Potassium Channel THIK-1 Regulates NLRP3 Inflammasome Activation. Glia 70, 1301-1316.

view

June 30, 2021

Development of CVN424: A Selective and Novel GPR6 Inverse Agonist Effective in Models of Parkinson Disease

Brice, N.L., Schiffer, H.H., Monenschein, H., Mulligan, V.J., Page, K., Powell, J., Xu, X., Cheung, T., Burley, J.R., Sun, H., Dickson, L., Murphy, S.T., Kaushal, N., Sheardown, S., Lawrence, J., Chen, Y., Bartkowski, D., Kanta, A., Hosea, N., Dawson, L.A., Hitchcock, S.H., Carlton, M.B. (2021) Development of CVN424: a selective and novel GPR6 inverse agonist effective in models of Parkinson’s Disease. J. Pharmacol. Exp. Ther. 377: 407-416.

view

December 1, 2020

First-Time Disclosure of CVN424, a Potent and Selective GPR6 Inverse Agonist for the Treatment of Parkinson’s Disease: Discovery, Pharmacological Validation, and Identification of a Clinical Candidate

Sun, H., Monenschein, H., Schiffer, H.H., Reichard, H.A., Kikuchi, S., Hopkins, M., Macklin, T.K., Hitchcock, S., Adams, M., Green, J., Brown, J., Murphy, S.T., Kaushal, N., Collia, D.R., Moore, S., Ray, W.J., English, N.M., Carlton, M.B.L, Brice, N.L. (2021) First-Time Disclosure of CVN424, a Potent and Selective GPR6 Inverse Agonist for the Treatment of Parkinson's Disease: Discovery, Pharmacological Validation, and Identification of a Clinical Candidate. J. Med Chem., 64: 9875–9890

view